Dyspepsia medical therapy
|
Dyspepsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspepsia medical therapy On the Web |
|
American Roentgen Ray Society Images of Dyspepsia medical therapy |
|
Risk calculators and risk factors for Dyspepsia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Ajay Gade MD[3]]
Overview
Dyspepsia is a symptom-based syndrome defined as one or more of epigastric pain, epigastric burning, postprandial fullness, or early satiation that is bothersome enough to impact normal activities, and which is thought to originate from the gastroduodenal region.[1] Dyspepsia is classified as either uninvestigated dyspepsia (symptoms without prior evaluation) or investigated dyspepsia, in which upper endoscopy has been performed to categorize the cause as organic or functional. Organic dyspepsia arises from an identifiable structural or metabolic etiology, whereas functional dyspepsia (FD) is diagnosed when no such cause is found after appropriate investigation.
Under the Rome IV criteria, FD is subclassified into two primary subtypes that may overlap: postprandial distress syndrome (PDS), characterized predominantly by meal-induced postprandial fullness and early satiation, and epigastric pain syndrome (EPS), characterized primarily by epigastric pain or burning unrelated to meals.[1] Functional dyspepsia affects approximately 7% of individuals in the general community and constitutes the majority of dyspepsia cases encountered in clinical practice, with most patients managed in primary care.[1]
Functional and uninvestigated dyspepsia share a similar stepwise treatment approach. Decisions around drug therapy are complicated by the fact that many earlier trials included patients with predominant heartburn within their dyspepsia definitions, a factor that artificially favored proton pump inhibitors (PPIs) — agents that are primarily indicated for acid reflux rather than true functional dyspepsia. Contemporary guidelines from the ACG/CAG (2017) and the British Society of Gastroenterology (BSG, 2022) provide the principal evidence-based frameworks for management.[2][1]
Medical Therapy
Initial Evaluation and Triage
The initial approach to dyspepsia is governed by identifying alarm features (which mandate prompt investigation) and by patient age, which determines the initial management strategy.
Alarm features requiring prompt upper endoscopy:
- Progressive dysphagia or odynophagia
- Unintentional weight loss
- Evidence of gastrointestinal bleeding (hematemesis, melena, or iron-deficiency anemia)
- Persistent vomiting
- Palpable epigastric mass or lymphadenopathy
- First-degree family history of upper gastrointestinal malignancy
- For patients ≥60 years of age: upper endoscopy is conditionally suggested to exclude organic pathology including malignancy, even in the absence of alarm features (ACG/CAG 2017, conditional recommendation, very low-quality evidence).[2]
- For patients <60 years of age without alarm features: a non-invasive Helicobacter pylori test and treat strategy is the recommended first-line approach, followed by empirical PPI therapy for those who test negative or remain symptomatic after eradication (ACG/CAG 2017, strong recommendation, high-quality evidence).[2]
The BSG 2022 guideline additionally recommends urgent endoscopy in patients aged ≥55 years who present with dyspepsia and weight loss, and in any patient with dysphagia, hematemesis, or evidence of upper gastrointestinal bleeding regardless of age.[1]
Differential Diagnosis of Dyspepsia:
| Condition | Key Features | Distinguishing Investigation |
|---|---|---|
| Functional dyspepsia | Epigastric pain, burning, fullness, or early satiation; no alarm features; chronic/relapsing course | Upper endoscopy (normal findings); H. pylori testing |
| Peptic ulcer disease | Epigastric pain; often hunger-related or nocturnal (duodenal ulcer); food may worsen (gastric ulcer); H. pylori or NSAID history | Upper endoscopy with biopsy; H. pylori testing |
| Gastroesophageal reflux disease (GERD) | Predominant heartburn and regurgitation; epigastric burning may overlap; not to be confused with dyspepsia when heartburn is the dominant symptom | Clinical diagnosis; 24-hour esophageal pH monitoring if atypical |
| Gastric or esophageal carcinoma | Progressive symptoms; weight loss; dysphagia; age ≥55; family history of GI cancer | Urgent upper endoscopy with biopsy |
| Gastroparesis | Early satiety, postprandial nausea and vomiting; often in diabetics or post-surgical patients | Gastric emptying scintigraphy (nuclear medicine) |
| Biliary colic / Cholelithiasis | Right upper quadrant or epigastric colicky pain, typically postprandial; fatty food intolerance | Abdominal ultrasound |
| Chronic pancreatitis | Epigastric pain radiating to back; alcohol history; worsened by eating | Serum lipase; computed tomography of abdomen |
| Celiac disease | Bloating, diarrhea, weight loss, malabsorption; may mimic FD | Anti-tissue transglutaminase IgA antibody; small intestinal biopsy |
| Medication-induced dyspepsia | History of NSAID, bisphosphonate, potassium, iron, theophylline, or digoxin use | Clinical history; medication review and withdrawal trial |
| Metabolic and systemic causes | Hypercalcemia, thyroid or parathyroid disease, diabetes mellitus, connective tissue disorders | Serum calcium, TSH, HbA1c, electrolytes |
| Zollinger-Ellison syndrome | Refractory or multiple peptic ulcers; secretory diarrhea; high-volume acid output | Fasting serum gastrin; secretin stimulation test |
| Ischemic heart disease | Epigastric discomfort with exertional component in at-risk patients; atypical anginal equivalent | Electrocardiogram; troponin; stress testing |
Pharmacotherapy
The medical therapy for dyspepsia follows a stepwise, evidence-based approach based on the underlying etiology and symptom subtype.[3]
Step 1: Helicobacter pylori Test and Treat
H. pylori test and treat is the recommended first-line strategy for all patients under 60 years without alarm features. The ACG/CAG 2017 guideline gives this a strong recommendation with high-quality evidence.[2] Preferred non-invasive tests include the urea breath test and stool antigen test; serology is not recommended for active infection diagnosis due to poor specificity.
A 2022 updated systematic review and meta-analysis of 29 RCTs (n = 6,781 H. pylori-positive FD patients) confirmed that eradication therapy was superior to control for symptom cure (RR of not being cured = 0.91; 95% CI: 0.88–0.94; NNT = 14; 95% CI: 11–21) and symptom improvement (RR = 0.84; 95% CI: 0.78–0.91; NNT = 9; 95% CI: 7–17).[4]
Choice of Eradication Regimen (2024 ACG Guideline):
The 2024 ACG Clinical Guideline on H. pylori treatment represents a major update, removing PPI-clarithromycin triple therapy as an empiric first-line option due to rising clarithromycin resistance rates in North America.[5]
| Regimen | Components | Duration | Recommendation Status |
|---|---|---|---|
| Optimized bismuth quadruple therapy (BQT) — Preferred first-line | PPI twice daily + bismuth subcitrate or subsalicylate 4 times daily + tetracycline 500 mg 4 times daily + metronidazole 500 mg 3–4 times daily | 14 days | Strongly recommended as first-line for treatment-naïve patients when antibiotic susceptibility is unknown; also preferred for patients who failed prior PPI-clarithromycin triple therapy |
| Rifabutin triple therapy — Alternative first-line | PPI twice daily + amoxicillin 1 g twice daily + rifabutin 150 mg twice daily | 14 days | Conditionally suggested as empiric alternative (patients without penicillin allergy) |
| Vonoprazan (PCAB)-amoxicillin dual therapy — Alternative first-line | Vonoprazan 20 mg twice daily + amoxicillin 1 g three times daily | 14 days | Conditionally suggested as empiric alternative; FDA-approved (2022) for H. pylori eradication |
| Vonoprazan (PCAB)-clarithromycin triple therapy | Vonoprazan + clarithromycin + amoxicillin | 14 days | Conditionally suggested over PPI-clarithromycin triple when clarithromycin susceptibility is unknown |
| PPI-clarithromycin triple therapy | PPI + clarithromycin + amoxicillin (or metronidazole) | 14 days | Recommended against as empiric first-line; only acceptable if clarithromycin susceptibility is confirmed |
Following treatment, confirmation of H. pylori eradication is recommended at least 4 weeks after completing antibiotic therapy (and ≥2 weeks after stopping any PPI) using the urea breath test or stool antigen test. For treatment-experienced patients with persistent infection, optimized BQT remains the preferred empiric regimen; susceptibility-guided therapy is preferred when culture or molecular testing is available.[5]
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides more potent and consistent acid suppression than conventional PPIs through a distinct mechanism. Phase 3 trials demonstrated vonoprazan-based regimens were superior to PPI-clarithromycin triple therapy for H. pylori eradication, including in clarithromycin-resistant strains. Vonoprazan received FDA approval for H. pylori eradication in 2022.[6]
For more details regarding H. pylori eradication, read the main article Helicobacter pylori infection medical therapy.
Step 2: Empirical Proton Pump Inhibitor Therapy
PPI therapy is the recommended empirical treatment for H. pylori-negative dyspepsia patients and for patients who remain symptomatic after successful H. pylori eradication (ACG/CAG 2017, strong recommendation, high-quality evidence).[2]
The PPIs are, depending on the specific agent, FDA-indicated for erosive esophagitis, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, H. pylori eradication, and duodenal and gastric ulcers; they are not specifically FDA-approved for functional dyspepsia. However, strong evidence-based guidelines support their use for this indication.
- A Cochrane systematic review and meta-analysis (2017) of 25 RCTs (n = 8,453 participants) found that PPIs were more effective than placebo for relieving global dyspepsia symptoms in FD (RR 0.88; 95% CI: 0.82–0.94; studies = 18; n = 6,172; NNTB = 11; moderate-quality evidence).[7]
- The BOND and OPERA studies (Talley et al., 1998), two large double-blind, randomized, placebo-controlled trials, established that omeprazole 20 mg once daily produced significantly greater complete symptom relief than placebo in patients with ulcer-like and reflux-like functional dyspepsia subtypes, but not in dysmotility-like dyspepsia, underscoring the importance of symptom subtyping.[8]
- The CADET-HN study (Veldhuyzen van Zanten et al., 2005), the first trial to directly compare omeprazole 20 mg once daily against ranitidine 150 mg twice daily, cisapride 20 mg twice daily, and placebo in H. pylori-negative primary care patients with dyspepsia (n = 512), demonstrated that omeprazole had significantly better treatment success at 6 months (31%) compared to cisapride (13%), placebo (14%) (p = 0.001), and was just above the statistical threshold versus ranitidine (21%) (p = 0.053). Omeprazole also produced significant quality of life improvements over other agents and placebo in all but one domain measured (p = 0.01 to 0.05).[9]
- The ENCORE study, a follow-up of patients from the OPERA trial, showed that omeprazole responders had fewer subsequent clinic visits than non-responders (1.5 vs. 2.0 visits over three months, p < 0.001), demonstrating a downstream healthcare utilization benefit of effective acid suppression.[8]
PPIs are most effective for the EPS subtype (epigastric pain or burning) and are less effective for the PDS subtype (postprandial distress). Standard agents include omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, typically administered once daily before the first meal for an initial 4–8 week trial. Low-dose PPIs demonstrate similar efficacy to standard-dose PPIs for functional dyspepsia.[7]
Long-term PPI use without a clear ongoing indication should be avoided. Risks with prolonged use include association with Clostridioides difficile infection, hypomagnesemia, vitamin B12 deficiency, osteoporosis, and chronic kidney disease. Patients on maintenance PPI should be periodically reassessed and considered for step-down to on-demand or low-dose therapy.
Step 3: H2-Receptor Antagonists
Histamine-2 receptor antagonists (H2RAs; famotidine, nizatidine) are an alternative acid-suppressive option, particularly for patients who cannot tolerate PPIs or in whom PPI use is contraindicated. H2RAs have been shown to have marked benefit in poor-quality trials (approximately 30% relative risk reduction) but only marginal benefit in good-quality trials. They are considered less effective than PPIs for dyspepsia and are regarded as a second-line acid-suppressive option.[3]
Step 4: Prokinetic Agents
Prokinetics are conditionally recommended as second-line therapy for FD patients not responding to PPI or H. pylori eradication therapy (ACG/CAG 2017, conditional recommendation, very low-quality evidence).[2] They are particularly rationale for the PDS subtype, in which delayed gastric emptying and impaired gastric accommodation may contribute to symptoms.
Prokinetic agents have been shown in a pooled meta-analysis to produce a relative risk reduction of up to 50% in FD symptoms; however, much of this earlier evidence was derived from studies of cisapride, which has since been withdrawn from the market and is now only available as an investigational agent due to serious cardiovascular adverse events (QTc prolongation and torsades de pointes). Publication bias has been cited as a further confounding factor in the earlier literature.[3]
Currently available prokinetic agents and their status:
| Agent | Mechanism | Dose | Notes |
|---|---|---|---|
| Metoclopramide | Dopamine D2 antagonist; 5-HT4 agonist | 10 mg three times daily before meals | Available in the USA; FDA label limits use to ≤12 weeks due to risk of tardive dyskinesia with long-term use; avoid in patients with history of movement disorders |
| Domperidone | Peripheral D2 antagonist | 10 mg three times daily before meals | Not available in the USA; widely used internationally; QTc prolongation risk requires electrocardiographic monitoring |
| Itopride | D2 antagonist and acetylcholinesterase inhibitor | 50 mg three times daily | Not available in the USA; evidence primarily from Asian and European RCTs; favorable tolerability profile |
| Acotiamide | Selective acetylcholinesterase inhibitor; muscarinic antagonist | 100 mg three times daily | Licensed for FD in Japan; significant efficacy for PDS subtype in controlled trials; not available in Western markets |
| Erythromycin | Motilin receptor agonist | Variable | Primarily used for gastroparesis; tachyphylaxis limits long-term utility; limited evidence specifically in FD |
| Cisapride | 5-HT4 agonist (mixed) | — | Withdrawn from market worldwide due to cardiac arrhythmia risk (QTc prolongation, torsades de pointes); available only as investigational agent |
Modern prokinetic agents such as metoclopramide and erythromycin have limited or no established efficacy in functional dyspepsia specifically and often result in substantial side effects. Tegaserod, a partial 5-HT4 agonist, also has limited evidence in functional dyspepsia and has been subject to market restrictions due to cardiovascular safety concerns.[3]
Step 5: Neuromodulators (Gut-Brain Modulators)
Neuromodulators are recommended as second- or third-line therapy for FD refractory to first-line treatments. The ACG/CAG 2017 guideline conditionally recommends tricyclic antidepressant (TCA) therapy (conditional recommendation, low-quality evidence).[2] The BSG 2022 guideline endorses TCAs as second-line gut-brain neuromodulators and provides additional guidance on other agents in this class.[1]
Tricyclic Antidepressants (TCAs):
TCAs are the best-evidenced neuromodulators in FD. Low-dose TCA therapy (below antidepressant doses) modulates visceral hypersensitivity and central pain processing. The large Functional Dyspepsia Treatment Trial (FDTT), a multicenter RCT, demonstrated that amitriptyline at 50 mg nightly resulted in a 3-fold greater odds of adequate relief compared to placebo specifically in patients with ulcer-like (EPS-type) functional dyspepsia (OR = 3.1; 95% CI: 1.1–9.0); the benefit was not seen in the dysmotility-like subtype, and escitalopram was not superior to placebo in either subtype.[10]
Common TCA agents and doses used in FD:
- Amitriptyline 10–50 mg at bedtime (most evidence in FD)
- Nortriptyline 10–75 mg at bedtime (better anticholinergic tolerability than amitriptyline)
- Imipramine 10–50 mg at bedtime
Adverse effects include dry mouth, constipation, urinary retention, sedation, blurred vision, and cardiac QTc prolongation. A baseline electrocardiogram is advisable in older adults or those with cardiac risk factors before initiating TCA therapy. Response rates of 64–70% have been reported in some older series, though these figures reflect selected populations.[3]
Selective Serotonin Reuptake Inhibitors (SSRIs):
SSRIs have not demonstrated efficacy superior to placebo for FD in controlled trials and are not recommended for FD as a primary therapeutic indication.[2][10] The ACG/CAG guideline does not support their use for this condition.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):
The 2022 BSG guideline states there is currently no evidence that SNRIs are efficacious as second-line gut-brain neuromodulators for global FD symptoms and does not recommend them for this indication.[1]
Mirtazapine:
Mirtazapine, a tetracyclic antidepressant with noradrenergic, 5-HT2C antagonist, and histamine H1 antagonist properties, has shown benefit in FD patients with prominent early satiation and weight loss. The 2022 BSG guideline conditionally suggests mirtazapine 15 mg once daily as a potential second-line treatment for FD associated with early satiation and weight loss, while noting that further RCTs are needed before a stronger recommendation can be made.[1]
5-HT1A Agonists:
Tandospirone 10 mg three times daily has demonstrated some efficacy as a second-line treatment for FD, predominantly in Asian populations (BSG 2022, conditional suggestion). Buspirone 10 mg three times daily has not demonstrated significant efficacy for FD in controlled trials; the 2022 BSG guideline does not recommend it for this indication.[1]
Pregabalin:
Pregabalin 75 mg once daily has shown some promise in FD in limited trial data. The 2022 BSG guideline conditionally suggests it may be efficacious but, given its status as a controlled substance, advises restriction to specialist settings pending further RCTs.[1]
Antacids and Simethicone
- Antacids (calcium carbonate, aluminum hydroxide, magnesium hydroxide) neutralize excess gastric acid and can provide short-term symptomatic relief. Despite widespread use, antacids and sucralfate were found to be no better than placebo in systematic literature reviews for functional dyspepsia, and they are not recommended as definitive therapies for FD.[3]
- Simethicone, a defoaming agent, has been found to be of some value for bloating and flatulence-related symptoms; one trial demonstrated potential benefit over placebo and another showed equivalence with cisapride (prior to its withdrawal). However, evidence remains limited and further robust RCT data are lacking. These agents are primarily used for on-demand symptomatic relief rather than as definitive treatments for FD.
- Antacids remain appropriate for use as adjuncts for mild or intermittent dyspeptic symptoms.
Non-Pharmacological Therapy
- Activity and lifestyle modification: Adequate rest, stress reduction, and regular low-impact physical activity are reasonable supportive measures.
- Dietary modification: Reduction of dietary fat, caffeine, alcohol, carbonated beverages, and spicy foods; eating smaller, more frequent meals; and identifying individual dietary triggers. Evidence for specific dietary interventions in FD remains limited, and individualization of advice is important.
- Traditional therapies used for dyspepsia include lifestyle modification, antacids, H2-receptor antagonists (H2-RAs), prokinetic agents, and antiflatulents. One of the most frustrating aspects of treating functional dyspepsia is that these traditional agents have been shown to have little or no definitive efficacy in well-controlled trials.[3]
- Psychological therapies: For FD not responding to pharmacological therapy, the ACG/CAG guideline suggests that psychological therapies should be offered (conditional recommendation, very low-quality evidence).[2] A 2022 systematic review and meta-analysis of 16 RCTs (n = 1,550 patients with FD) found that psychotherapeutic interventions — including cognitive behavioral therapy (CBT), hypnotherapy, and mindfulness-based stress reduction (MBSR) — significantly reduced gastrointestinal symptoms, depression, and anxiety in patients with FD compared to control conditions.[11]
- Complementary and alternative medicine: The ACG/CAG guideline does not recommend the routine use of complementary and alternative medicines for FD due to insufficient evidence (conditional recommendation, very low-quality evidence).[2]
- NSAID and medication review: NSAIDs are among the most commonly prescribed drugs globally and their use significantly increases the risk of dyspepsia. If possible, NSAIDs should be discontinued, dose-reduced, or switched to a COX-2 selective inhibitor. Where continuation is necessary, co-prescription of a PPI is appropriate. Other implicated medications include bisphosphonates, potassium supplements, iron preparations, theophylline, digoxin, oral antibiotics (especially ampicillin and erythromycin), glucocorticoids, niacin, gemfibrozil, narcotics, colchicine, quinidine, estrogens, and levodopa.
Stepwise Treatment Algorithm
| Step | Patient Group | Recommended Action | Guideline Basis |
|---|---|---|---|
| 1 | All patients with uninvestigated dyspepsia, age <60, no alarm features | Non-invasive H. pylori test and treat (urea breath test or stool antigen test preferred) | ACG/CAG 2017 (strong recommendation, high evidence); BSG 2022 |
| 2a | H. pylori positive | Eradication therapy (optimized BQT preferred 2024 ACG guideline); reassess for eradication at ≥4 weeks post-treatment | 2024 ACG H. pylori guideline |
| 2b | H. pylori negative, or symptoms persist after successful eradication | Empirical PPI therapy (4–8 weeks); reassess response | ACG/CAG 2017 (strong recommendation, high evidence) |
| 3 | Symptoms persist after PPI; EPS subtype (pain/burning) | Continue or optimize PPI; consider adding TCA at low dose | ACG/CAG 2017; BSG 2022 |
| 4 | Symptoms persist after PPI; PDS subtype (postprandial distress) | Add prokinetic therapy (metoclopramide or domperidone where available); consider mirtazapine if early satiation with weight loss | ACG/CAG 2017 (conditional); BSG 2022 |
| 5 | Refractory to PPI and prokinetic/TCA therapy | Refer to gastroenterology; consider psychological therapy (CBT, hypnotherapy, MBSR); reassess diagnosis; review for gastroparesis, celiac disease, and other organic causes | ACG/CAG 2017 (conditional); BSG 2022 |
| Age ≥60 or alarm features present | Any age with alarm features; age ≥60 with new or persistent dyspepsia | Upper endoscopy; do not apply test and treat empirically without excluding malignancy | ACG/CAG 2017 (conditional); BSG 2022 (strong) |
Special Populations
Elderly patients (≥60 years): Elderly patients have a substantially higher prevalence of organic pathology, including peptic ulcer disease, reflux esophagitis, and upper gastrointestinal malignancy. Upper endoscopy is conditionally suggested in this age group to exclude organic disease before initiating empirical therapy.[2] Aspirin was associated with dyspepsia and/or heartburn in elderly community-dwelling patients (OR = 1.6; 95% CI: 1.2–2.2), and nonaspirin NSAIDs similarly increased risk (OR = 1.8; 95% CI: 1.3–2.6).[12] TCA use in elderly patients requires careful monitoring due to heightened anticholinergic toxicity, fall risk, and cardiac adverse effects.
Patients on chronic NSAIDs: NSAID-induced dyspeptic symptoms do not reliably predict underlying mucosal injury. Management options include NSAID discontinuation or dose reduction, switching to a COX-2 selective inhibitor, or adding a PPI as gastroprotection. H. pylori testing and eradication is also recommended in NSAID users who develop dyspepsia, as concurrent infection significantly amplifies peptic ulcer risk.
Patients with diabetes mellitus: Diabetes is an important cause of gastroparesis, which may mimic or coexist with FD. Gastric emptying scintigraphy should be considered when gastroparesis is clinically suspected (prominent postprandial nausea, vomiting, early satiation with documented weight loss). Glycemic optimization may improve gastric motility in diabetic gastroparesis.
Pregnancy: Non-pharmacological approaches (dietary modification, small meals, positional changes) should be first-line. Antacids (calcium carbonate, magnesium hydroxide) are generally considered safe. Metoclopramide is commonly used for nausea in pregnancy. Famotidine is considered relatively safe. PPIs are not specifically FDA-approved for functional dyspepsia but are used when clinically necessary and are regarded as generally low-risk in pregnancy. TCAs should generally be avoided in pregnancy.
Refractory functional dyspepsia: Patients with severe or refractory symptoms should be referred to gastroenterology. Evaluation should include: (a) consideration of repeat upper endoscopy if prior investigation is remote or incomplete; (b) gastric emptying scintigraphy if gastroparesis is clinically suspected; (c) assessment for psychiatric comorbidities (anxiety, depression, somatization); (d) consideration of neuromodulator therapy; and (e) referral for gut-directed psychological therapy (CBT, gut-directed hypnotherapy).[1] The routine use of upper GI motility studies is not recommended in FD but may be selectively useful in patients where gastroparesis is strongly suspected (ACG/CAG 2017, conditional recommendation).[2]
In patients with Rome IV FD who are concurrently consuming opioids, opioid cessation should be actively encouraged; a combination of opioid cessation and a neuromodulator has been associated with an NNT of 5.7 to achieve clinically meaningful symptom improvement.[13]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, Hungin P, Overshott R, Vasant DH, Rudd S, Winning RC, Corsetti M, Ford AC (2022). "British Society of Gastroenterology guidelines on the management of functional dyspepsia". Gut. 71 (9): 1697–1723. doi:10.1136/gutjnl-2022-327737. PMID 35798375 Check
|pmid=value (help). - ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017). "ACG and CAG Clinical Guideline: Management of Dyspepsia". Am J Gastroenterol. 112 (7): 988–1013. doi:10.1038/ajg.2017.154. PMID 28631728.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Mönkemüller K, Malfertheiner P (2006). "Drug treatment of functional dyspepsia". World J Gastroenterol. 12 (17): 2694–2700. doi:10.3748/wjg.v12.i17.2694. PMID 16718755.
- ↑ Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P (2022). "Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis". Gut. 71 (10): 1967–1975. doi:10.1136/gutjnl-2021-326583. PMID 35022266 Check
|pmid=value (help). - ↑ 5.0 5.1 Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC (2024). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". Am J Gastroenterol. 119 (9): 1730–1753. doi:10.14309/ajg.0000000000002968. PMID 39231499 Check
|pmid=value (help). - ↑ Kanu JE, Soldera J (2024). "Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis". World J Gastroenterol. 30 (9): 1213–1223. doi:10.3748/wjg.v30.i9.1213. PMID 38577188 Check
|pmid=value (help). - ↑ 7.0 7.1 Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P (2017). "Proton pump inhibitors for functional dyspepsia". Cochrane Database Syst Rev. 11: CD011194. doi:10.1002/14651858.CD011194.pub2. PMID 29161458.
- ↑ 8.0 8.1 Talley NJ, Meineche-Schmidt V, Paré P, Duckworth M, Räisänen P, Pap A, Kordecki H, Schmid V (1998). "Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)". Aliment Pharmacol Ther. 12 (11): 1055–1065. doi:10.1046/j.1365-2036.1998.00410.x. PMID 9845395.
- ↑ Veldhuyzen van Zanten S, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P (2005). "A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study". Am J Gastroenterol. 100 (7): 1477–1488. doi:10.1111/j.1572-0241.2005.40280.x. PMID 15984968. Vancouver style error: initials (help)
- ↑ 10.0 10.1 Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Lacy BE, Lehr KM, Seifert RM, Boone RH, Jiang X, Brenner DM, Quigley EM, Pieper MS, Zinsmeister AR (2015). "Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study". Gastroenterology. 149 (2): 340–349. doi:10.1053/j.gastro.2015.04.020. PMID 25921377.
- ↑ Wei Z, Xing X, Tantai X, Xiao C, Yang Q, Jiang X, Hao Y, Liu N, Wang Y, Wang J (2022). "The Effects of Psychological Interventions on Symptoms and Psychology of Functional Dyspepsia: A Systematic Review and Meta-Analysis". Front Psychol. 13: 827220. doi:10.3389/fpsyg.2022.827220. PMID 35279421 Check
|pmid=value (help). - ↑ Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ 3rd (1996). "Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly". Dig Dis Sci. 41 (7): 1275–1280. doi:10.1007/BF02065549. PMID 8737671.
- ↑ Nikaki K, Sawyer L, Akande F, Vasant DH (2021). "Clinical Characteristics and Outcomes of Patients With Rome IV Functional Dyspepsia Who Consume Opioids: A Real-World Study". Neurogastroenterol Motil. 33 (12): e14215. doi:10.1111/nmo.14215. PMID 33929099 Check
|pmid=value (help).